Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 6, 2007
A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings.
Show full opinionHide full opinion
A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings.
DON'T BUY
DON'T BUY
February 6, 2007
Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.
Show full opinionHide full opinion
Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks.
PAST TOP PICK
PAST TOP PICK
January 22, 2007
(A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story.
Show full opinionHide full opinion
(A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story.
BUY
BUY
December 18, 2006
Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions.
Show full opinionHide full opinion
Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions.
WAIT
WAIT
December 1, 2006
Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling.
Show full opinionHide full opinion
Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling.
TOP PICK
TOP PICK
November 8, 2006
Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings.
Show full opinionHide full opinion
Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings.
PAST TOP PICK
PAST TOP PICK
November 6, 2006
(A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents.
Show full opinionHide full opinion
(A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents.
DON'T BUY
DON'T BUY
October 18, 2006
Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment.
Show full opinionHide full opinion
Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment.
TOP PICK
TOP PICK
October 16, 2006
Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing.
Show full opinionHide full opinion
Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing.
BUY
BUY
October 2, 2006
Management is great. It is trading at a low price. Believes it is a buy.
Show full opinionHide full opinion
Management is great. It is trading at a low price. Believes it is a buy.
TOP PICK
TOP PICK
September 27, 2006
Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes.
Show full opinionHide full opinion
Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes.
BUY
BUY
September 1, 2006
Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through.
Show full opinionHide full opinion
Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through.
TOP PICK
TOP PICK
August 31, 2006
Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents.
Show full opinionHide full opinion
Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents.
PAST TOP PICK
PAST TOP PICK
August 4, 2006
(A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock.
Show full opinionHide full opinion
(A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock.
TOP PICK
TOP PICK
July 31, 2006
Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings.
Show full opinionHide full opinion
Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings.
Showing 16 to 30 of 140 entries